Team

Eddy is a repeat entrepreneur and an award-winning mathematician, with over 20 years of experience designing novel AI algorithms and building world-class teams to take on some of the most challenging technological challenges in signal processing, computer vision, and AI.

Gil is a world-renowned technologist, who previously served as CTO of Flatiron Health (acquired by Roche for $2B) growing the technology team from two engineers to a team of over 350 across software, DevOps, IT, security, product design, and data science. At NeuraLight he is responsible for all cross-functional scaling and growth, and is also an avid startup investor, advisor and mentor.

Rivka is a Pharmaceutical Executive who spent over 26 years at Teva Pharmaceuticals. During her tenure at Teva, Rivka held various roles including Head of Global Innovative Research and Development (IR&D), where she managed a group of 700 researchers focusing on CNS and Autoimmune. Rivka also led Search and Evaluation, and was Head of Global Speciality Regulatory Affairs at Teva. Rivka earned her PhD at the Weizmann Institute of Science (Biochemistry) and completed postdoctoral work at Princeton University (Molecular Biology).

Tzvika has over 15 years of experience managing complex interdisciplinary projects and operations. Previously, Tzvika established and managed all operations for Palantir Israel, and more recently managed all launching operations for Israeli micro-fulfillment unicorn Fabric. Tzvika holds a Bachelor’s in Management from Ben-Gurion University, and an MBA from Reichman University.

Eitan is an experienced global clinical and regulatory affairs professional, with a clinical experience of over 20 years, working in medical centers, healthcare companies and the medical device industry. Eitan holds a PhD from the faculty of medicine in Tel Aviv university, and has a vast knowledge of innovative medical technology, with a strong business perspective.

Eli joined Koch Industries in 2019 and launched the Israeli office of Koch Disruptive Technologies focusing on long-term investments in Israeli companies. Previously, Eli served as Director General of the Prime Minister’s Office, and as a consultant at McKinsey & Company. Eli serves as Director on multiple startup boards, and has vast experience in business transformation and strategic and corporate development, along with founder mentorship. In addition to his corporate activities, Eli is a board member at Birthright Israel, The Israel Democracy Institute, and the Wexner Israel Advisory Board.

Jon Soberg is Managing Partner at MS&AD Ventures, an early-stage venture capital firm focused on the future of finance, risk assessment, and building a sustainable society. Jon has made over 120 investments across 5 continents and has held more than 40 board positions. Prior to becoming an investor, Jon was a serial entrepreneur and operator, with an IPO exit at Adforce. Jon has a Master’s degree in Engineering, a CFA, and is an MBA and Palmer Scholar at Wharton. Jon is ranked #13 on Business Insider’s Seed 100 list of top seed investors.

Board director Avast. Former P&G executive. Co-founder and first CEO and Chairwoman at Trax retail, Partner at Next Ventures.

Jon is an associate with Koch Disruptive Technologies, where he is responsible for identifying, evaluating, and executing on growth equity and venture capital investment opportunities. Prior to joining KDT, Jon worked at Goldman Sachs focusing on cross capital structure investment opportunities. Jon serves as an Observer on multiple startup boards, sharing unique insights, and leveraging his network to create bridges between Israel and the US.

Prof. Südhof is a world-renowned neuroscientist who won a Nobel prize for his work on synaptic transmission. Currently heading the Südhof lab at Stanford, he’s considered by many one of the world’s leading researchers of Alzheimer’s Disease.

Prof. Rascol is a world-renowned neurologist and clinical pharmacologist, an expert in Parkinson’s and movement disorders, as well as drug development for PD. Prof. Rascol has served as the secretary of the International Parkinson & Movement Disorders Society and as the Chair of its European section. He is either serving or has previously served as associate editor for the Movement Disorder Journal, the Journal of Neural Transmission and as a member of the editorial board of Lancet Neurology, Neurology, CNS Drugs and the European Journal of Neurology, and  has published more than 500 articles in international scientific journals.

Prof. Fred Lublin is a world-renowned authority on the treatment of MS, whose work has redefined the clinical course of the disease. Prof. Lublin serves as Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center. As a paid consultant and shareholder, he advises us on designing digital markers for MS and its progression.

Al Roth is a professor of Economics at Stanford University. He has worked widely on market design, including in health care, for which he won the 2012 Nobel Prize in Economics.

Prof. Ruth Djaldetti is a world-renowned neurologist and researcher. She previously was a research fellow at Columbia University, and currently serves as the Head of the Movement Disorder Center at Rabin Medical Center, and is a professor at TAU Medical School.

Marta Bralic Kerns is the Founder & CEO of Pomelo Care, a company transforming maternity and neonatal outcomes through personalized, evidence-based care for moms and babies. Previously, Marta was the Senior Vice President of Business Development at Flatiron Health – the leader in oncology real world evidence – where she led strategic partnerships, corp dev, and new product initiatives. Marta started her career in McKinsey’s healthcare practice working on healthcare payment reform after graduating magna cum laude from Harvard with a degree in Government and Computer Science.

Nick Brown serves as the Chief Growth Officer at PathAI, directing the Digital Diagnostic division and Strategic Partnerships group. In his previous role within PathAI as the Chief Commercial Officer for Biopharma, Nick established and expanded an extensive network of data and distribution partnerships. Before his tenure at PathAI, Nick was Head of International Business at Flatiron Health, a prominent health-tech firm acquired by the Roche Group in 2018. He led the company’s largest growth initiative to expand into three international markets and oversaw all partnership activities, commercial negotiations, and customer discussions. He also supported strategic partnerships including Flatiron’s research collaboration with the US Food and Drug Administration and National Cancer Institute.

Afik has over 20 years of experience in healthcare analytics, entrepreneurship and innovation leadership. He is a Co-founder of VC-backed Assured Allies, an insur-tech company dedicated to making longevity sustainable. Previously Afik served as Head of the Innovation Lab at PwC’s Healthcare Advisory. Afik earned his MBA from Duke University and his MD from Ben-Gurion University.